(LONDON) January 11, 2004 --Britannia Pharmaceuticals announces today the availability of the APO-go Pre-Filled Syringe (PFS), an easier to use presentation for Parkinson’s disease patients using apomorphine by continuous infusion with an APO-go pump.
Patients requiring a continuous subcutaneous infusion of apomorphine use an APO-go pump to administer their drug. The new APO-go PFS contains a 5mg/ml concentration of apomorphine hydrochloride which is ready for transfer to a plastic syringe specifically designed for use with an APO-go pump. There is no longer a need to break ampoules thereby reducing the time of the preparation procedure.
The advantages to the new APO-go PFS include:
• Quick and simple
• Pre-dilution ensures accurate dosage
• Reduced likelihood of spillage or contamination
• No need to break ampoules thereby eliminating associated risks
• Lower cost to NHS compared with separate APO-go and saline ampoules
James Carter, Marketing Manager for Britannia Pharmaceuticals commented, “The APO-go pump has been a major benefit to patients who require apomorphine infusions, being small, discreet and relatively easy to use. With our new APO-go PFS the time to prepare an infusion has been further reduced and its use eliminates the risk of injury that was possible when using glass ampoules and needles. Finally, being pre-diluted and ready for a quick and simple transfer, APO-go PFS represents good pharmaceutical practice.”
For more information:
Last updated on: 27/08/2010
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.